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OBJECTIVES We sought to evaluate the relative efficacies of three possible therapeutic strategies for patients
with multivessel coronary artery disease (CAD), stable angina, and preserved ventricular
function.
BACKGROUND Despite routine use of coronary artery bypass graft surgery (CABG) and percutaneous
coronary intervention (PCI), there is no conclusive evidence that either one is superior to
medical therapy (MT) alone for the treatment of multivessel CAD.
METHODS The primary end point was defined as cardiac mortality, Q-wave myocardial infarction (MI),
or refractory angina requiring revascularization. All data were analyzed according to the
intention-to-treat principle.
RESULTS A total of 611 patients were randomly assigned to either a CABG (n 203), PCI (n 205),
or MT (n  203) group. The one-year survival rates were 96.0% for CABG, 95.6% for PCI,
and 98.5% for MT. The rates for one-year survival free of Q-wave MI were 98% for CABG,
92% for PCI, and 97% for MT. After one-year follow-up, 8.3% of MT patients and 13.3%
of PCI patients underwent to additional interventions, compared with only 0.5% of CABG
patients. At one-year follow-up, 88% of the patients in the CABG group, 79% in the PCI
group, and 46% in the MT group were free of angina (p  0.0001).
CONCLUSIONS Medical therapy for multivessel CAD was associated with a lower incidence of short-term
events and a reduced need for additional revascularization, compared with PCI. In addition,
CABG was superior to MT for eliminating anginal symptoms. All three therapeutic regimens
yielded relatively low rates of cardiac-related deaths. (J Am Coll Cardiol 2004;43:1743–51)
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mhe most appropriate treatment for patients with multives-
el stable coronary artery disease (CAD) remains unknown.
here is no recent evaluation of medical therapy (MT)
ersus surgical therapy in the modern era of pharmacologic
reatment, since novel surgical techniques have been per-
ormed. Furthermore, the use of percutaneous coronary
ntervention (PCI) is increasing more rapidly than surgery,
espite a lack of evidence regarding its superiority to either
T or surgical approaches.
See page 1752
Medical therapy for patients with multivessel CAD has
hanged considerably in recent years. Current therapeutic
trategies, including aggressive modification of risk factors
From the *Heart Institute of the University of Sa˜o Paulo, Sa˜o Paulo, Brazil; and the
Mayo Clinic, Rochester, Minnesota. Financial support was provided, in part, by a
esearch grant from the Zerbini Foundation, Sa˜o Paulo, Brazil. Dr. William
eintraub acted as Guest Editor of this paper.
Manuscript received February 17, 2003; revised manuscript received August 7,003, accepted August 15, 2003.nd intermittent use of nitrates, beta-blockers, calcium
hannel blockers, angiotensin-converting enzyme inhibi-
ors, and more recently, 3-hydroxy-3-methylglutaryl-
oenzyme A reductase inhibitors, have improved the out-
omes of patients with CAD (1,2). Nonetheless, the rate of
ajor cardiovascular events is considerable in medically
reated patients, particularly those with multivessel disease
3).
For patients with multivessel disease, the benefits of
oronary artery bypass graft surgery (CABG) are well
ocumented with respect to symptoms and, in some groups,
ortality and morbidity (4–6). Refinements in PCI have
mproved the treatment of patients with CAD (7,8). How-
ver, the rapidly expanding use of PCI is based on a
erceived benefit in comparison with the use of CABG or
T, but these perceptions are from selected subsets of
atients (9). In fact, no study has demonstrated a mortality
enefit over MT in patients with stable CAD (10).
The specific question of whether PCI or surgical treat-
ent offers any advantage over MT in patients with stable
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MASS-II at One Year May 19, 2004:1743–51ngina and multivessel disease remains unanswered. Be-
ause PCI is unlikely to be more effective than CABG in
educing mortality or myocardial infarction (MI) in this
atient population, its potential benefits are measured more
eadily in terms of symptomatic and functional outcomes. In
his respect, several factors complicate the choices among
atients who are appropriate candidates for all three thera-
ies—namely, CABG, MT, or PCI. For example, the
ncidence of the most common adverse event—restenosis—
emains high despite the reduction observed after stent
lacement in PCI patients (11,12). Thus, there is no
bjective comparison of the three therapeutic strategies for
atients with multivessel disease (13). The Medicine, An-
ioplasty, or Surgery Study (MASS-II), a randomized trial,
as therefore designed to compare the relative efficacy of
ither CABG, PCI, or MT in the management of patients
ith symptomatic multivessel CAD.
ETHODS
atient selection. Patients with angiographically docu-
ented proximal multivessel coronary stenosis of more than
0% by visual assessment and documented ischemia were
onsidered for inclusion. Ischemia was documented by
ither stress testing or the typical stable angina assessment
f the Canadian Cardiovascular Society (CCS) (class II or
II). Patients were enrolled and randomized if there was
greement on the part of the surgeon and interventionist
hat revascularization could be attained by either strategy.
atients gave written, informed consent and were randomly
ssigned to a treatment group. The Ethics Committee of
he Heart Institute approved the trial, and all procedures were
erformed in accordance with the Helsinki Declaration.
Exclusion criteria included unstable angina or acute MI
equiring emergency revascularization, ventricular aneurysm
equiring surgical repair, left ventricular ejection fraction of
40%, a history of PCI or CABG, and single-vessel
isease. Patients were also excluded: if they had a history of
ongenital heart disease, valvular heart disease, or cardio-
yopathy; if they were unable to understand or cooperate
ith the protocol requirements or to return for follow-up; or
f they had left main coronary artery stenosis of 50% or
ore, or suspected or known pregnancy or another coexist-
ng condition that was a contraindication to CABG or PCI.
reatment intervention. In this trial, all patients were
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
CCS  Canadian Cardiovascular Society
ECG  electrocardiogram/electrocardiographic
MASS-II  Medicine, Angioplasty, or Surgery Study-II
MI  myocardial infarction
MT  medical therapy
PCI  percutaneous coronary interventionlaced on an optimal medical regiment consisting of a Mtepped-care approach using nitrates, aspirin, beta-blockers,
alcium channel blockers, angiotensin-converting enzyme
nhibitors, or a combination of these drugs, unless contra-
ndicated. Hydroxymethylglutaryl-coenzyme A reductase
nhibitors were also prescribed, along with a low-fat diet on
n individual basis. The medications were provided for free
y the Heart Institute. Patients were then randomized to
ontinue with aggressive medical therapy alone or to un-
ergo PCI or CABG concurrently with MT.
Trial operators were required to perform optimum coro-
ary revascularization in accordance with current best prac-
ice. Equivalent revascularization was encouraged but not
andatory.
For patients assigned to PCI, the procedure was available
ithin three weeks after the assignment. Devices used for
atheter-based therapeutic strategies, including stents, la-
ers, directional atherectomy, and balloon angioplasty, were
vailable to the interventionist. Angioplasty was performed
ccording to a standard protocol (14). Glycoprotein IIb/IIa
gents were not used. Successful revascularization in the
CI group was defined as a residual stenosis of 50%
eduction in luminal diameter with Thrombolysis In Myo-
ardial Infarction (TIMI) flow grade 3.
Patients assigned to the CABG group underwent the
peration within 12 weeks after assignment. Complete
evascularization was accomplished, if technically feasible,
ith saphenous vein grafts, internal mammary arteries, and
ther conduits such as radial or gastroepiploic arteries.
tandard surgical techniques (15) were used under hypo-
hermic arrest with blood cardioplegia. No off-pump
ABG was performed.
ollow-up. Adverse and other clinical events were tracked
rom randomization. Patients were assessed with follow-up
isits every three months until one year at the Heart
nstitute. Patients underwent a symptom-limited treadmill
xercise test, according to a modified Bruce protocol, at
aseline and by the end of one year, unless contraindicated.
e considered exercise test results as positive when exer-
ional angina developed or when we observed an ST-
egment with an abnormal depression (horizontal or
ownsloping of 1 mm for men and 2 mm for women) at
.08 s after the J point. Routine examinations included
lectrocardiography at rest, echocardiography, and routine
lood tests every six months. Patients assigned to the PCI
roup also underwent routine coronary angiography at six
onths.
Coronary arteriography was performed by use of the
ones or Seldinger technique. For assessment of ventricular
unction, patients underwent contrast left ventriculography
t baseline in the right anterior oblique projection, and
jection fraction was calculated by the Dodge formula (16).
Symptoms of angina were graded according to severity,
rom 1 to 4, as previously defined (17). Angina was
onsidered refractory only when patients had been treated
ith full anti-ischemic therapies to their level of tolerance.
yocardial infarction was defined as the presence of signif-
i
(
w
m
c
c
d
e
r
h
a
t
t
u
e
t
a
S
d
g
s
r
m
c
f
p
u
a
t
b
m
w
a
C
S
a
t
c
t
t
t
C
R
B
p
c
b
p
t
r
f
s
d
i
p
b
p
p
r
c
C
2
h
d
a
f
t
c
t
g
i
s
i
a
C
1
(
b
T
e
g
C
r
n
i
f
p
t
w
(
M
2
p
w
D
a
N
S
C
H
r
t
t
m
1745JACC Vol. 43, No. 10, 2004 Hueb et al.
May 19, 2004:1743–51 MASS-II at One Yearcant new Q waves in at least two electrocardiographic
ECG) leads or symptoms compatible with MI associated
ith creatine kinase, MB fraction concentrations that were
ore than three times the upper limit of the reference range.
The predefined primary end point was the incidence of
ardiac mortality, MI, or refractory angina requiring revas-
ularization. The performance of a revascularization proce-
ure was considered an end point for patients in any group,
xcept for those assigned to PCI, who had additional
outine coronary angioplasty. All patients in the PCI group
ad routine planned angiograms at six months. These
ngiograms were not considered to be end points because
hey were done independently of symptoms. However,
herapeutic PCI or CABG performed during an episode of
nstable angina at any time during follow-up was consid-
red to be an end point and was applied equally across all
hree arms of therapy. Secondary end points included
ngina status and stroke or cerebrovascular accident.
tatistical analyses. The sample size was calculated to
etect a two-fold difference of event rates between any two
roups, with a power of 80% and a two-sided level of
ignificance of 0.05%. On the basis of the two-year event
ate of 8.58% from the Randomized Intervention Treat-
ent of Angina (RITA) trial (18), assumptions included 41
omposite events for each group to be reached during
ollow-up. It was determined that a minimum of 191
atients in each group was necessary to conduct this study,
sing the formula of Makuch and Simon (19). All data were
nalyzed according to the intention-to-treat principle rather
han treatment received.
The event-free survival time was defined as the interval
etween random assignment and the occurrence of a pri-
ary end point or the latest follow-up. Event-free survival
as estimated by the Kaplan-Meier method, and differences
mong groups were assessed by means of the log-rank test.
ontinuous variables were estimated as the mean value 
D and compared among the three groups by one-way
nalysis of variance followed by the multiple comparisons
est. The chi-square and Fisher exact tests were used to
ompare qualitative variables among the three groups. All
ests were two-tailed, and p  0.05 was considered statis-
ically significant. Statistical analysis was performed with
he Statistical Analysis System (SAS Institute, Cary, North
arolina).
ESULTS
aseline variables. A total of 20,769 patients who had a
resumptive clinical diagnosis of CAD and who underwent
oronary arteriography were screened at the Heart Institute
etween May 1995 and May 2000. Of these, 18,692 (90%)
atients either refused to participate or refused a specific
reatment or did not meet the clinical or angiographic
equirements for study inclusion. The most frequent reasons
or exclusion were single-vessel disease, unstable angina,
tenosis 70%, previous PCI or CABG, and valvular tisease. The remaining 2,077 (10%) patients who had
ndications for revascularization were enrolled. Of these
atients, 1,466 (71%) could not be randomly assigned
ecause of specific protocol restrictions. Of these, 991 (68%)
atients refused to participate in this trial, and 474 (32%)
atients specifically refused the surgical procedure. The
emaining eligible 611 (29%) patients who met all entry
riteria were randomly assigned to one of three groups:
ABG (n  203; 33%), PCI (n  205; 34%), or MT (n 
03; 33%). A total of 254 (42%) randomly assigned patients
ad double-vessel disease, and 357 (58%) had triple-vessel
isease.
The vital status of all randomly assigned patients was
scertained in May 2001. The minimal duration of
ollow-up was one year. Randomization created balanced
reatment groups with respect to important prognostic
haracteristics, as depicted in Table 1. That is, patients in all
hree therapeutic groups were similar with respect to age,
ender, employment status, severity of angina, use of med-
cation, and history of MI, diabetes mellitus, or hyperten-
ion. Patients assigned to the three groups were also similar
n terms of resting and exercise ECG findings, as well as
rteriographic and ventriculographic characteristics.
At study entry, 79% of the participating patients had
CS class II or III angina, 268 (43.9%) had a history of MI,
67 (27.3%) showed ECG evidence of previous MI, 183
30.0%) smoked cigarettes, and 487 (79.7%) were receiving
eta-blockers (Tables 1 and 2).
reatment outcomes. There were no significant differ-
nces in in-hospital major complications among the three
roups. The hospital mortality rates of patients in the
ABG group were similar. The same result was observed in
elation to Q-wave MI. No patient in the CABG group
eeded in-hospital angioplasty or emergency bypass graft-
ng. On the other hand, major abnormalities of respiratory
unction were observed in 10 (5%) patients; 5 (2.5%)
atients had mediastinitis; and 2 (1%) patients required a
horacotomy for reasons other than revascularization. There
ere six strokes (3%) in the CABG group and two strokes
1%) in the PCI group (Table 3).
EDICAL THERAPY. During the one-year follow-up, of the
03 patients assigned to receive MT, 10 (5%) had an uncom-
licated MI, 12 (6%) were referred for CABG, and 4 (1.97%)
ere referred for angioplasty because of refractory angina.
uring the follow-up period, three (1.5%) patients died of MI
nd three (1.5%) other patients had a cerebrovascular accident.
o patient in this group was lost to follow-up.
URGICAL THERAPY. Of the 203 patients assigned to the
ABG group, 198 (98%) received the assigned treatment.
owever, four (2.0%) patients received MT because they
efused the surgical procedure; these patients were alive at
he end of the first year of follow-up. Initial revasculariza-
ion was performed within three weeks of assigned treat-
ent in 47% of the patients. The remaining 53% receivedhe assigned treatment within 12 weeks (mean 7 weeks).
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MASS-II at One Year May 19, 2004:1743–51Each patient who underwent CABG had an average
f 3.3  0.8 vessels bypassed. All intended vessels were
rafted in 74% of patients. At least one internal thoracic
rtery was used for grafting in 92% of patients, and two
nternal thoracic arteries and a radial artery were used in
6% of patients. The epigastric artery was used in 10% of
atients.
The median hospital stay after CABG was 10 days.
uring follow-up, only one patient in this group underwent
CI, and four (2%) patients had an uncomplicated MI.
evertheless, in this follow-up period, eight (4%) patients
ied of MI, and three (1.5%) other patients had a cerebro-
ascular accident.
ORONARY ANGIOPLASTY. Among the 205 patients as-
igned to the PCI group, 194 (95%) received the assigned
Table 1. Characteristics of 611 Patients Assign
Multivessel Disease
Characteristic
MT
(n  20
Demographic profile
Age (yrs) 60  9
Age 65 yrs 36
Female 31
Employed 29
Current or past smoker 33
Medical history
Myocardial infarction 39
Hypertension 55
Diabetes mellitus 36
CCS class II or III angina 78
Laboratory values (mmol/l)
Total cholesterol 5.74  1
LDL cholesterol 3.83  0
HDL cholesterol 0.96  0
Triglycerides 2.01  0
Positive treadmill test 47
Angiographic findings
Mean ejection fraction (%) 68  7
Double-vessel disease 41
Triple-vessel disease 59
LAD disease 89
Data are presented as the mean value  SD or % of patien
abnormal rest electrocardiogram.
CABG  coronary artery bypass graft surgery; CCS 
low-density lipoprotein, respectively; LAD  left anterio
percutaneous coronary intervention.
Table 2. Use of Medications During Follow-U
Medication
MT
(n  203)
Aspirin 80%
Long-acting nitrates 73%
Beta-blockers 68%
Calcium channel antagonists 61%
HMG-CoA reductase inhibitors 68%
ACE inhibitors 29%
Insulin 13%
Oral hypoglycemic agents 22%
ACE  angiotensin-converting enzyme; HMG-CoA  3-
Table 1.reatment, 6 (3%) underwent CABG as their initial treat-
ent, and 2 (0.98%) died before treatment. The deaths were
ue to automobile and occupational accidents. In addition,
hree (1.5%) patients received MT because they refused the
CI procedure; these patients were alive at the end of the
rst year of follow-up.
Angioplasty as the initial revascularization was performed
ithin three weeks of treatment assignment in 70% of
atients (mean 2.7 weeks). Each patient who underwent
CI had an average of 2.1  0.7 vessels dilated. Multivessel
CI was performed in 141 (73%) patients.
Immediate angiographic success was achieved in 92% of
atients in whom PCI was attempted, and at least one stent
as implanted in 140 (72%) patients. Complete revascular-
zation (as defined by successful intervention in all major
One of Three Groups for
PCI
(n  205)
CABG
(n  203)
60  9 60  9
38 34
33 28
27 24
27 32
52 41
61 63
23 29
78 86
5.69  1.06 5.53  1.09
3.80  0.93 3.70  0.93
0.98  0.26 0.96  0.26
2.04  0.82 1.91  0.95
33 56
67  8 67  9
42 42
58 58
93 93
me patients had both angina and positive treadmill test or
ian Cardiovascular Society; HDL and LDL  high- and
ending coronary artery; MT  medical therapy; PCI 
Patients Assigned to One of Three Groups
PCI
 205)
CABG
(n  203)
Mean
Value p Value
80% 70% 77% 0.024
41% 12% 42% 0.0001
61% 44% 58% 0.0001
30% 44% 45% 0.0001
73% 49% 63% 0.00001
30% 21% 27% 0.085
9% 11% 11% 0.424
14% 35% 37% 0.0001
xy-3-methylglutaryl-coenzyme A; other abbreviations as ined to
3)
.01
.88
.26
.93
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May 19, 2004:1743–51 MASS-II at One Yearessels with at least 70% stenosis) was achieved in 41% of
atients. Two (1.03%) additional patients in whom PCI was
ncomplicated but unsuccessful were referred for elective
ABG during the initial hospitalization; two (1.03%)
atients required repeat PCI before discharge.
During follow-up, 18 (8.78%) patients underwent further
CI and 7 (3.4%) underwent CABG. Nevertheless, in this
ollow-up period, 9 (4.5%) patients died of MI, 16 (8.3%)
ad an uncomplicated MI, and 2 had a cerebrovascular
ccident (Table 4).
VENT-FREE SURVIVAL. The rates of event-free survival—
amely, the combined incidence of cardiac mortality, MI, or
efractory angina requiring revascularization—were signifi-
antly different among patients in the three therapeutic
roups (p  0.0001). Patients assigned to the PCI group
ad more events (n 50) than did patients in the MT (n
9) or CABG (n  13) groups, despite the fact that repeat
CI was not considered as an end point, except when the
atients had unstable angina (Fig. 1).
ARDIAC-RELATED MORTALITY. There were no significant
ifferences among the cumulative cardiac-related mortality
urves associated with the three therapeutic strategies (Fig.
). There were nine deaths in the PCI group, eight deaths
n the CABG group, and three deaths in the MT group (p
0.23). The cumulative survival rates at one year for
atients assigned to each group were 96% for PCI, 96% for
ABG, and 98% for MT.
DDITIONAL REVASCULARIZATION. The greatest differ-
nce among the three groups was the frequency of addi-
ional interventions (surgery or angioplasty) required during
he first year of follow-up. Only one additional intervention
as required among patients in the CABG group, but 16
dditional interventions were required for patients in the
T group and 25 for patients in the PCI group with
able 3. Frequency of Major In-Hospital Events
PCI
(n  205)
CABG
(n  203)
eath 5 (2.4%) 5 (2.5%)
-wave MI 2 (1.0%) 2 (1.0%)
mergency CABG 2 (1.0%) —
mergency PCI 2 (1.0%) —
troke 2 (1.0%) 6 (3.0%)
o differences between groups were significant.
MI  myocardial infarction; other abbreviations as in Table 1.
Table 4. One-Year Outcomes of the Randomi
MT
(n  203)
Death 3 (1.5%)
Q-wave MI 10 (5.0%)
CCS class II or III angina 126 (63.6)
CVA 3 (1.5%)
CABG 12 (6.0%)
PCI 4 (1.97%)CVA  cerebrovascular accident; other abbreviations as in Tablesnstable angina (p  0.000015) (Fig. 3). This proportion
ncludes patients undergoing another PCI after six-month
ngiography. Even though this was not considered in the
rimary end-point analysis, PCI was considered an end
oint if it was performed in patients with unstable angina at
ny time.
After one year of follow-up, additional surgical revascu-
arization had been performed in no patients in the CABG
roup, in 12 (6%) patients in the MT group, and in 7 (3.4%)
atients in the PCI group (p  0.008) (Fig. 4). Also during
his period, only one patient in the CABG group and four
atients (1.97%) in the MT group underwent subsequent
ngioplasty, as compared with 18 (8.78%) patients in the
CI group (p  0.0001) (Fig. 5). It should be emphasized
hat subsequent angioplasty in the PCI group was per-
ormed on the basis of restenosis with persistent ischemia, as
videnced by either angina or positive scintigraphic findings,
nd not merely on the basis of anatomic findings at the time
f the protocol-driven angiogram.
econdary end points. Patients treated with surgical re-
ascularization were most likely to be free of anginal
ymptoms after one year of follow-up. In contrast, a marked
resence of anginal symptoms was observed among patients
andomly assigned to the MT group. More specifically, only
4 (36%) patients in the MT group were free of anginal
ymptoms after one year of follow-up, as compared with 120
59%) patients in the CABG group and 107 (52%) patients
n the PCI group. A statistically significant benefit was
ound for the CABG group compared with the MT group
p  0.0001), as well as for the PCI compared with MT
roup (p  0.001), but not for the CABG compared with
CI group (p  0.16). None of the study patients in any
reatment group had refractory angina (CCS class III or
V); moreover, we observed a reduction in the rates of
ositive exercise tests at the end of follow-up for all patients.
owever, this reduction was greater in the CABG group
36%) (p  0.0001) and PCI group (18%) (p  0.0005)
han in the MT group (5%) (p  0.45).
ISCUSSION
he largest randomized trial performed at a single institu-
ion, MASS-II, compared the relative efficacy of three
urrent therapeutic strategies for patients with symptomatic
ultivessel CAD. We found no significant difference be-
ween the CABG, PCI, and MT groups with regard to
roups
PCI
(n  205)
CABG
(n  203) p Value
9 (4.5%) 8 (4.0%) 0.23
16 (8.3%) 4 (2.0%) 0.01
87 (45.3%) 75 (39%) 0.0001
2 (1.0%) 3 (1.5%) 0.29
7 (3.5%) — 0.0001
18 (8.78%) 1 (0.5%) 0.008zed G1 and 3.
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MASS-II at One Year May 19, 2004:1743–51ardiac death or acute MI during one-year follow-up.
owever, angina requiring new revascularization was higher
n the PCI group compared with the other treatments. The
ABG-treated patients had better symptomatic relief than
atients who underwent the PCI or MT strategy.
Our results are consistent with the Coronary Artery
urgery Study (CASS) trial, in which no difference was seen
etween patients in the surgical and medical groups in terms
f mortality, Q-wave MI, or event-free survival rates after
ve years of follow-up. In the CASS trial, a subgroup of
atients with preserved ventricular function and mild stable
ngina was more likely to experience event-free survival with
T alone, even in the presence of three-vessel CAD.
igure 1. Probability of survival free of cardiac mortality, unstable angina re
reatment groups: medical therapy (MT), coronary artery bypass graft surg
igure 2. Probability of survival free of cardiac-related mortality among p
n Figure 1.After one-year follow-up study in the Asymptomatic
ardiac Ischemia Pilot (ACIP) (20) trial, better outcomes
ere observed in patients treated with surgical revascular-
zation, even though this trial had different inclusion crite-
ia. Mortality and morbidity, as well as MI, were less
ommon in patients assigned to the revascularization treat-
ent strategy than in patients in the angina-guided group,
ut not less common than in patients in the ischemia-
uided group.
Compared with other therapeutic strategies, surgical
herapy was superior in MASS-II in improving event-free
urvival. This superiority probably reflected a low perioper-
tive complication rate, symptomatic improvement, and the
g revascularization, and myocardial infarction among patients in the three
CABG), and percutaneous coronary intervention (PCI).
s in the three treatment groups: MT, CABG, and PCI. Abbreviations asquirinatient
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May 19, 2004:1743–51 MASS-II at One Yearompleteness of revascularization, as well as the use of
rterial conduits. This eliminates the need for repeat inter-
ention, at least during the one-year follow-up period.
In major trials (21–26) that enrolled about 4,130 patients
ith stable multivessel CAD who were followed up from
ne to five years, data showed no differences in mortality
etween patients in the PCI group and those in the CABG
roup. These trials were similar to MASS-II, except that a
hird randomized arm—MT alone—was not included as a
reatment strategy. In contrast, in the RITA-2 trial (25),
mong patients with CAD considered suitable for either
CI or MT, and especially among patients with more severe
ngina, early intervention with PCI was associated with
igure 3. Freedom from additional revascularization after study entry amon
s in Figure 1.
igure 4. Freedom from additional CABG after study entry among patie
igure 1.reater symptomatic improvement. However, nonfatal MI
nd cardiac-related death were more common in the PCI
rm, although many of the infarcts were deferred by
eriprocedural enzyme leaks. In the Bypass Angioplasty
evascularization Investigation (BARI) trial (26), a worse
rognosis was documented in patients who had diabetes, a
nding that we did not observe in MASS-II, but our study
ncluded only a few diabetic patients.
More recently, in the Arterial Revascularization Therapy
tudy (ARTS), data were analyzed from one year of
ollow-up of 1,205 patients who were randomly assigned to
ndergo stent implantation or CABG (27). In ARTS, there
as no statistically significant difference between the two
ients in the three treatment groups: MT, CABG, and PCI. Abbreviations
the three treatment groups: MT, CABG, and PCI. Abbreviations as ing patnts in
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MASS-II at One Year May 19, 2004:1743–51roups regarding the rates of death, stroke, or MI. However,
he stent group was associated with a greater need for repeat
evascularization. Similarly, in our study, only one patient in
he CABG group required further revascularization, and
2% of those in the PCI group underwent a second
evascularization. The need for repeat revascularization was
he greatest difference among our groups.
Furthermore, after a minimum of one year of follow-up
n the Stent or Surgery (SoS) trial (28), the use of stents
educed the need for repeat revascularization, compared
ith previous studies that used balloon angioplasty, al-
hough the rate remained significantly higher than that in
atients managed with CABG. Medical therapy reduces MI
nd death in patients with stable CAD. Four randomized,
ontrolled trials have compared PCI with MT. These
tudies have demonstrated that PCI resulted in an improve-
ent in angina and exercise tolerance compared with MT,
ut they also suggest that MT may be preferable to PCI
ith respect to the risk of cardiac events.
Nonetheless, the Atorvastatin Versus Revascularization
reatment trial (29) showed that in low-risk patients with
table CAD, aggressive lipid-lowering therapy is at least as
ffective as angioplasty and usual care in reducing the
ncidence of major cardiac events.
On the other hand, ongoing efforts toward a better
efinition of the role of PCI in the treatment of stable CAD
ill be addressed by the Clinic Outcomes Utilizing Revas-
ularization and Aggressive druG Evaluation (COUR-
GE) trial, which compares aggressive MT with aggressive
T plus PCI during three to seven years of follow-up in
atients with document myocardial ischemia. The hypoth-
sis is that PCI plus MT is superior to MT alone for a
rimary end point of death or MI.
igure 5. Freedom from additional PCI after study entry among patients inDespite the larger number of procedures performed in the tCI group, patients in the CABG group had a greater
egree of revascularization and somewhat more favorable
tatus with respect to anginal symptoms. The fact that
urgeons grafted more vessels than were dilated by inter-
entional cardiologists reflects conceptual differences be-
ween the two therapeutic strategies. Cardiologists perform-
ng angioplasty procedures have an opportunity to revise
heir initial decision on the basis of the clinical and
ngiographic outcomes of each lesion attempted or consid-
red for intervention. Surgeons tend to use grafts for arteries
ith less stenosis (50%), as well as for those with more
tenosis. Not surprisingly, on the basis of the number of
essels treated, the degree of revascularization achieved
urgically appeared to be more complete than that achieved
ith coronary angioplasty (p  0.0001). Other ongoing
rials of PCI involving patients with multivessel disease have
lso shown a frequent need for CABG in the angioplasty
roups, ranging from 19% to 31% (18,23–25).
Although many new trials are being performed to eluci-
ate the best therapeutic option for stable CAD with
ultivessel disease, we distinguished and contrasted the
ASS-II trial from ongoing trials. Ours is the only one that
ill be able to compare PCI, CABG, or MT for the
anagement of these patients, and our results should help
o determine which one would be the best approach in
ong-term follow-up.
onclusions and clinical implications. The MASS-II
rial showed no difference in cardiac death or acute MI
mong patients in the CABG, PCI, or MT group. How-
ver, it did show a significantly greater need for additional
evascularization procedures in patients who underwent
CI. Our finding of comparable mortality and morbidity
ates for patients who underwent CABG or MT suggests
ree treatment groups: MT, CABG, and PCI. Abbreviations as in Figure 1.the thhat MT is a reasonable alternative for patients with
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May 19, 2004:1743–51 MASS-II at One Yearultivessel CAD who refuse surgical therapy. Therefore,
he patient must be made aware of the possibility that
urther revascularization procedures may be required during
he follow-up period.
Moreover, important developments in PCI have taken
lace since this trial was started. The use of glycoprotein
Ib/IIa antiplatelet agents, the long-term use of the oral
ntiplatelet agent clopidogrel, and the development and
ore widespread application of a drug-eluting stent hold
he promise of a significant reduction in restenosis and
evascularization rates. In addition, surgery without cardio-
ulmonary bypass could have an important effect on surgical
esults in the future. Similarly, the aggressive MT and
ifestyle prescriptions with comprehensive risk factor mod-
fication will also enhance the MT strategy.
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